Background: Changes in lung density on computed tomography (CT) are common after stereotactic ablative radiotherapy (SABR) and can confound the early detection of recurrence. We performed a systematic review to describe post-SABR findings on computed tomography (CT) and positron-emission tomography (PET), identify imaging characteristics that predict recurrence and propose a follow-up imaging algorithm. Methods: A systematic review was conducted of studies providing detailed radiologic descriptions of anatomic and metabolic lung changes after SABR. Our search returned 824 studies; 26 met our inclusion criteria. Data are presented according to PRISMA guidelines. Results: Acute changes post-SABR predominantly appear as consolidation or ground glass opacities. Late changes often demonstrate a modified conventional pattern of fibrosis, evolving beyond 2 years after treatment. Several CT features, including an enlarging opacity, correlate with recurrence. Although PET SUVmax may rise immediately post-SABR, an SUVmax P 5 carries a high predictive value of recurrence. Conclusions: CT density changes are common post-SABR. The available evidence suggests that recurrent disease should be suspected if high-risk CT changes are seen with SUVmax P 5 on PET. Further studies are needed to validate the predictive values of such metrics, and for advanced analysis of CT changes to allow early detection of potentially curable local recurrence.
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Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), is now a standard treatment option for patients with stage I non-small cell lung cancer (NSCLC) who are unfit for surgery or who are medically operable but refuse surgery [1] [2] [3] . Image-guided SABR is characterized by large fraction sizes coupled with accurate and precise delivery [4] . Although data from randomized trials comparing SABR with surgery are not available, non-randomized single-institution and populationbased studies have reported short/medium-term clinical outcomes comparable to those of primary surgery, with reported local control rates of over 90% [2, 5, 6] . Comparable overall survival (OS) rates in operable patients is also supported by a Markov model-based decision analysis [7] .
Radiation-induced CT lung changes after SABR differ from those observed after conventionally fractionated radiotherapy. Lung changes characteristic to conventional RT consist of CT changes with straight borders corresponding to conventional treatment field edges [8] . SABR employs complex beam arrangements to conform high-dose regions to the tumor and create steep dose gradients around the target volume, with a relatively large volume of lung receiving low/intermediate doses (e.g. 5-40 Gy). In some instances, CT changes after SABR can develop as mass-like patterns that mimic the appearance of recurrent disease [9, 10] .
Although CT changes after SABR are common, and in-field recurrences are uncommon [11] , distinguishing between the two entities is of paramount importance in patients who may be candidates for salvage therapy, including surgical resection [12] . Current follow-up relies mainly on CT imaging, with positron emission tomography (PET) or biopsy when recurrence is strongly suspected. The drawback of over-investigation is unnecessary imaging and the risks of invasive procedures [13, 14] , while under-investigation of a growing recurrence risks missing the window of opportunity for salvage therapy. However the optimal imaging paradigm after SABR is yet to be defined.
As fitter patients with longer life expectancies are now undergoing treatment with SABR, understanding long-term imaging changes will take on increased importance, yet a standardized approach to follow-up and interpretation of imaging after SABR is lacking. The goals of this study were to systematically review the literature describing CT and PET findings following lung SABR, to identify imaging characteristics that might predict for local recurrence, and to propose imaging guidelines based on the available evidence for early detection of local recurrence after SABR.
Methods
A systematic review of the literature was performed according to PRISMA guidelines [15] . We searched for English-language papers published between 1995 and June 2011 that met the following criteria:
(1) Studies reporting on primary lung tumors, or tumors metastatic to lung, treated with SABR. (2) Studies providing a detailed radiologic description of benign or malignant lung changes on follow-up CT or PET imaging.
The following exclusion criteria were used:
(1) Studies only reporting toxicity or tumor response but not detailed radiologic changes. (2) Case studies. (3) Review articles.
Search strategy
Studies were identified by searching the MEDLINE (n = 439) and EMBASE (n = 332) databases. These searches were completed in June 2011. Search strategies are described in online Appendix e1 and selection process is illustrated in Fig. 1 . After elimination of duplicate papers, 439 pertinent papers were identified based on their titles and abstracts. Of these, 43 were selected for detailed review, and 22 ultimately met our inclusion criteria and were selected for this review. 8729 conference abstracts from 2005 to 2011 were searched by textword: stereotactic, yielding 385 studies for additional review. Of these, 10 were selected for detailed review, one abstract was selected and its corresponding unpublished manuscript was obtained from the author as a personal communication [16] . Finally, a review of reference lists of selected papers yielded two additional abstracts of interest and both were selected for the study. One abstract was obtained through expert suggestion, and was included in this review. A total of 23 articles and three abstracts were reviewed, summarized in online Appendix e2 and e3.
Results

Acute and late CT lung changes post-SABR
The pattern of changes in lung parenchyma on CT post-SABR has been described in several studies (Table 1 and Appendix e4) [9, [17] [18] [19] [20] [21] [22] and can generally be categorized as acute (within 6 months, corresponding to pneumonitis) or late (after 6 months, corresponding to fibrosis) [18, 23] .
Several papers have classified acute changes into one of five general patterns: diffuse consolidation, patchy consolidation, diffuse ground-glass opacities (GGO), patchy GGO, and no change (Table 1 ) [9, [17] [18] [19] . Representative images showing each of these changes are well illustrated in reference [9] . These classifications are based on descriptions of changes after conventional radiotherapy [24, 25] . Based on weighted averages across studies, the overall incidences of increased CT density in the acute setting was 62%, the majority of which is consolidation (45% of patients), with GGO less common. Dahele et al. analyzed the temporal pattern of CT changes and found that the actuarial median time to acute CT change was 17 weeks [9] .
Late changes include modified conventional (consolidation, volume loss, and bronchiectasis similar to but less extensive than conventional radiation fibrosis), scar-like fibrosis (linear opacity in the region of the original tumor), mass-like fibrosis and no change, again illustrated in the study by Dahele et al. [9] . The terms ''diffuse'' versus ''patchy'' have also been objectively defined according to size criteria and severity [18] . Across studies, the mean incidence of all CT lung changes was 91% of cases. The predominant CT density patterns were modified conventional (62%) and less commonly scar-like (15%) and mass-like fibrosis (14%). The appearance of mass-like fibrosis appears to peak at 1 to 2 years post-SABR [9] . A study by Matsuo et al. analyzed only mass-like consolidation and noted its appearance in 68% of cases, at a median of 5 months post-SABR [26] .
Other classification schemes for CT patterns have also been reported (Appendix e4) [20] [21] [22] . The incidence of early and late radiation-induced lung changes ranged from 54-79% to 80-100%, respectively.
Although early findings of severe radiation pneumonitis (RP) are predictive of late changes [9] they are not a pre-requisite [10] . Acute and late CT changes have also been correlated with dose and volume as summarized in Appendix e5 [20, [27] [28] [29] [30] . The graphical RP is generally correlated with doses above 20 Gray [29] .
Post-SABR CT findings suggestive of recurrence
Three studies directly analyzed the radiological appearance of recurrent disease in the post-SABR setting [10, 26, 31] . A summary of post-SABR imaging characteristics of recurrent disease is presented in Table 2 . The presence of an enlarging mass as a sign of recurrence is supported by all three studies. According to Kato et al., the most reliable indicator of local recurrence is increased size of the opacity after 12 months and additional CT findings suggestive of recurrence include a bulging margin, disappearance of air bronchograms and appearance of pleural effusion [31] . Of these, disappearance of air bronchograms and emergence of pleural effusion tended to appear early (within 12 months) and has been suggested as an aid to the early detection of recurrence. Matsuo et al. similarly found a correlation between an increase in size after 12 months and recurrence (p < 0.01). They found that recurrence was not predicted by the initial timing of the abnormality, conformity of the abnormality to dose distribution or the presence of ec- Abbreviations: computed tomography (CT), stereotactic ablative radiotherapy (SABR), ground glass opacity (GGO), three-dimensional conformal radiotherapy (3DCRT), RapidArc (RA). 3/50 Initial regrowth with recurrence n = 3 (2 pathology proven) At 5.9, 9.2, and 12.0 months; shape: solid n = 3 Initial regrowth without recurrence n = 14 (4 pathology proven)
Median time 21.4 months (8.6-35.6); shape: solid n = 9
Abbreviations: computed tomography (CT), stereotactic ablative radiotherapy (SABR).
tatic (distended/dilated) bronchi, some of which had been previously found to be suggestive of recurrence after conventional RT [26] . An enlarging mass may be sensitive, but not specific for recurrence as Takeda et al. report that the diagnosis of only a minority of patients with an enlarging mass was ultimately recurrence, based upon biopsy and further imaging studies [10] .
Expected metabolic findings on post-SABR PET
The role of 2-fluoro-2-deoxy-D-glucose (FDG)-PET in staging and evaluation of treatment response after conventional radiotherapy treatment is well understood [32] . An increase in standardized uptake value (SUV) is normally a sign of increased metabolic activity of tumor cells, which is a marker for tumor recurrence. However, in the post SABR setting, FDG avidity can also be related to normal acute radiation inflammatory response of lung tumors/ parenchyma [33] .
Several studies report normal tumor response values after SABR either as stable SUV or as a decline to background SUV [33] [34] [35] [36] [37] [38] [39] [40] . Transient rises can occur within the first 6 months after SABR, but usually not over an SUVmax of 5, consistent with acute postradiation normal tumor/tissue response (Table 3) [33, 36, 41, 42] . Henderson et al. noted a trend in the expected SUVs post-SABR; tumors with low pre-SABR SUVs were correlated with transient rises at 2 weeks post-SABR, whereas high pre-SABR SUVs were correlated with a post-SABR SUV decline at 2 weeks [36] .
Post-SABR metabolic findings of recurrence FDG-PET is commonly considered when local recurrence is suspected on CT imaging [36] . However, the use of PET in the evaluation of treatment response and detection of tumor recurrence after SABR is controversial. Some authors have suggested that metabolic changes on PET may provide an earlier indicator of tumor recur- rence than tumor size on CT, even arguing for routine PET followup imaging and prompting a pilot study on routine PET imaging post-SABR [36] , which remains investigational at present. PET may incorrectly identify patients at risk for recurrence, subjecting patients to the unnecessary risk of biopsy [14] . The limited availability of PET imaging in many centers further restricts its use in clinical practice. Due to the low incidence of local recurrences, studies examining their metabolic response signature are limited. A selected summary of FDG-PET values associated with both tumor response and local failure is provided in Table 3 . The total number of local recurrences in these 12 PET reports is very small (n = 24), follow-up is heterogenous, and the PET imaging strategies vary. Acknowledging this, the following preliminary observations are made: (i) SUVmax associated with recurrence may fail to decline or it increases over time, sometimes after an initial fall [34, 35, 39, 40] , (ii) if a PET scan is done on CT suspicion of recurrence then an SUVmax of 5 or more has generally been reported as indicative of recurrence, and if the scan is performed 3-6 months after SABR in an attempt to predict response, then an SUVmax of 5 or more has also been associated with a higher risk of recurrence [10, 16, 41, 43] , (iii) transient fluctuations in SUVmax have been reported, for example, recurrences may exhibit a transient initial SUV decrease [34, 35] , perhaps as the effects of acute radiation pneumonitis resolve before increased metabolic activity of tumor cells is detected. A transient decrease and subsequent increase in SUV has also been associated with apparent infection rather than recurrence [36] .
Only one study examined the positive predictive values (PPV) and negative predictive values (NPV) of a PET SUVmax cutoff for discriminating recurrence from post-SABR changes. Data from Chang et al. use a cutoff of SUVmax = 5 on FDG PET approximately 3-6 months post-SABR for predicting recurrence, finding a PPV of 83% and a NPV of 75% after a median follow-up of 31 months. In addition, SUVmax at 9 months was also correlated with development of recurrence ( [16] and associated unpublished manuscript). A separate study, presented only in abstract form, used an SUVmax cut-off of 5.0 at 3 months post-SABR and found improved local control with the SUVmax < 5 group (97.1% if SUVmax 6 5, vs. 78.8% if SUVmax > 5, p = 0.001) at 2 years, with a trend toward improved OS [43] . The performance of FDG-PET in these circumstances may change as the follow-up duration increases.
The limited data available suggest that 3-9-months post-SABR acute radiation changes may be resolving, allowing the metabolic activity of recurrent tumors to be more reliably detected, and that an SUVmax threshold of 5 at 3-6 months post-SABR may serve as a useful cut-off value for identifying lesions at high risk of subsequent local failure. This may not apply equally to lesions that were initially PET negative or weakly FDG-avid nor should PET findings be interpreted in isolation.
Recommendations for follow-up imaging
Based on the above findings, a proposed algorithm for imaging follow-up of SABR patients who are candidates for salvage treatment is shown in Fig. 2 . The primary imaging modality is CT thorax with contrast. In the absence of data, a frequency of 3-6 months is suggested, at least for the first year, thereafter the frequency might be tailored to whether the patient is medically operable (e.g. 6-12 m, depending on time frame), or not (e.g. annually), and the suspicion of recurrence (increased frequency if recurrence is a possibility).
FDG-PET is indicated when recurrence is suspected on CT imaging as demonstrated by an enlarging mass with 20% increase in sum of diameters (SOD) and absolute increase in SOD of at least 5 mm from baseline measurements post-SABR, based on RECIST 1.1 criteria [44] , with or without the presence of other high-risk features on CT. These include sequentially enlarging mass-like lesion, opacity enlargement after 12 months, bulging margin, disappearance of air bronchograms, linear margin disappearance, ipsilateral pleural effusion, or lymph node enlargement.
When FDG-PET imaging is obtained, it should be performed preferably on the same machine or on a standardized machine, and residual increases in SUV even 1 year after SABR should not automatically be defined as a recurrence. The use of routine PET/ CT at a predefined time point is still subject to investigation and, although useful in the setting of prospective clinical trials, cannot be recommended for routine follow-up at this time without current evidence to support it, particularly given very low rates of local recurrence, the limited availability of FDG-PET in many centers, and the high costs involved. Biopsy or resection should be considered on a case by case basis, taking into consideration the safety, availability of salvage options and the clinical suspicion for recurrence.
The limited evidence suggests that when SUVmax equals 5 or greater, recurrence should be highly suspected, and a biopsy or resection should be considered if safe. Some patients may have ⁄ Enlargement of CT density: as described by RECIST 1.1 by an increase in the sum of the diameters (SOD) of the target lesion by at least 20% from baseline (i.e. post-SABR nadir size) and absolute increase in SOD of at least 5 mm [44] . High-risk features: sequential enlargement on repeat CT, opacity enlargement after 12 months, bulging margin, disappearance of air bronchograms, linear margin disappearance, ipsilateral pleural effusion or lymph node enlargement. Abbreviations: Stereotactic ablative radiotherapy (SABR), computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), standardized uptake values (SUV).
recurrences that are not FDG avid, this is a particular concern if the original primary had a low SUV, and therefore in patients with SUVmax < 5 who have suspicious CT findings, biopsy should still be considered.
Operable patients can be considered for surgical salvage options whereas non-surgical salvage options can be considered in medically inoperable patients, preferably in prospective study protocols and with appropriate counseling for the expected increase in risk of severe toxicity. Outcomes from repeated use of SABR for in-field salvage have not been reported, however SABR has been used in patients who have previously received fractionated radiotherapy to the chest, with higher risks of toxicity [45] .
Discussion
CT density changes are common post-SABR, yet high-level evidence to guide discrimination between recurrence and fibrosis is lacking. This is particularly important in patients who are candidates for salvage therapy in whom the inability to distinguish these scenarios is especially concerning. Benign CT lung changes follow common acute and late patterns, appearing predominantly as consolidation within the first 6 months after treatment, with a modified conventional pattern of fibrosis emerging 6 months to years after treatment. An enlarging CT opacity after SABR is the most frequently reported feature of recurrence. Although PET SUVmax may transiently rise immediately post-SABR and persist for over 12 months without recurrence, SUVmax P 5 may serve as a useful cutoff for recurrence.
Advances in the field of SABR and CT/PET imaging in lung cancer continues to emerge [46, 47] . The issue of discriminating between benign fibrosis and recurrence is expected to take on increasing clinical importance in the coming years. Radiographic changes post-SABR will be encountered more frequently as the use of SABR for the treatment of early stage NSCLC increases, as the use of screening CT increases the detection of early stage disease, and as fitter patients with longer life expectancies are treated. The early detection of recurrence is especially important in the medically operable patient population or patients for whom curative surgical salvage treatments are still available. This study is the first, to our knowledge, to systematically review the literature on the discriminative value of imaging and provide structured recommendations based on the available evidence. The fact that these appear to reflect contemporary clinical practice is encouraging, however they also point to deficiencies in the current evidence base. Our algorithm improves upon one presented previously by RTOG 0618, by providing more high-risk features on CT and including specific SUVmax cutoffs, again based on a systematic review of the literature [48] .
A standardized definition of recurrence becomes especially important when comparing results across studies. Several Radiation Therapy Oncology Group (RTOG) clinical trials (0813, 0915, 0236, 0618) define local recurrence as an increase in tumor size as noted on CT imaging, along with either increased SUV on FDG-PET to original baseline levels, or biopsy proof of disease [48] . Recognizing the inability to obtain biopsy proof in all patients, the available evidence currently supports a definition of a recurrence as meeting either of two criteria: (1) increase in tumor size on CT imaging with SUVmax P5, or (2) pathology-proven disease. Where clinically appropriate, radiological findings should be confirmed pathologically with biopsy and/or resection. The presence of any malignant cells on biopsy should indicate recurrence, regardless of their viability, since assessment of viability after SABR has not been validated.
Although historical studies have reported lung changes after conventionally fractionated radiotherapy or chemoradiotherapy [8] , which tend to be less conformal than that of SABR, to our knowledge no study has rigorously scored morphological changes for direct comparison across these treatment modalities. Limited conclusions can be drawn from two similar studies that measured hounsfield unit (HU) density changes after either SABR [49] or chemoradiotherapy [50] , whereby the HU changes observed after SABR appear larger at each dose level. A current study is underway using HU density changes pooled from several centers, including patients treated with SABR, radiotherapy alone, and chemoradiotherapy, however the results will not be available for several months.
The conclusions of this study must be considered in the context of its strengths and limitations. Large studies examining this question are lacking, and studies vary in their patient selection, radiotherapy doses, follow-up regimens, and CT reporting criteria. Biopsy proof of recurrence was not obtained in the vast majority of patients, and definitions of recurrence varied between studies. SUV readings from FDG-PET scans can vary between institutions using different protocols and can fluctuate due to differences in blood glucose levels and PET agents used [35, 42] . The individual studies reported here were mainly retrospective, and independent validation of many predictive factors is lacking.
There are limitations inherent in our follow-up imaging recommendations, as they are based on data detailing only 35 total local/ in-field recurrences as seen on CT or PET. The most reliable indicator for recurrence is an enlarging mass, and additional high-risk features based on results of a single study were also included in our algorithm to help guide treatment and would require further validation. We acknowledge that our post-SABR SUVmax recommendations are based on SUVs gathered from both routine and non-routine PET/CT data, however we feel these results can be extrapolated to the setting of PET/CT at time of suspected recurrence. To validate and refine these recommendations, more studies are needed. Although the evidence is imperfect, the algorithm presented provides a framework that can be tested prospectively and modified in the future, and may assist clinicians who are currently following SABR patients, until further data becomes available.
Future directions include the objective quantification of CT changes; studies examining CT density, CT-based volumetric assessment and other quantification methods are emerging [49] . Additional imaging studies with larger sample sizes and longer follow-up times are needed to detect the number of recurrences required to draw more robust conclusions. A notable challenge in comparing sequential CT chest images after SABR may be lung volume retraction due to lung fibrosis, however this may be amenable to deformable image registration, another potential area of future study [49, 51] . Further characterization of expected SUV fluctuations with time may also help to distinguish abnormal SUV rises that may be correlated with recurrence. Recent data suggests pre-treatment SUVmax P6 significantly predicts local recurrence after SABR [47] , and one may argue for tailored follow-up schedules for such higher risk patients, a concept that requires validation. Future studies should also present receiver-operator characteristic curves and standard metrics such as sensitivity and specificity. These data will allow for a refinement of the preliminary management algorithm presented herein.
In conclusion, as SABR becomes more widely used in clinical practice, the detection of local recurrence during follow-up becomes increasingly important. This systematic review suggests that post-SABR lung changes demonstrate common acute and late patterns on CT. Furthermore, although the available evidence is limited, recurrence after SABR generally correlates with sequential opacity enlargement on follow-up CT imaging and SUV of P5. More studies, including those rigorously analyzing CT and PET cutoffs for prediction of recurrence are urgently needed to facilitate early detection of potentially treatable recurrence while preventing unnecessary invasive interventions for benign disease.
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